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Abstract
Although single-photon-emitting radiotracers have long been the standard for renal functional molecular imaging, recent years
have seen the development of positron emission tomography (PET) agents for this application. We provide an overview of renal
radionuclide PET radiotracers, in particular focusing on novel 18F-labelled and 68Ga-labelled agents. Several reported PET
imaging probes allow assessment of glomerular filtration rate, such as [68Ga]ethylenediaminetetraacetic acid ([68Ga]EDTA),
[68Ga]IRDye800-tilmanocept and 2-deoxy-2-[18F]fluorosorbitol ([18F]FDS)). The diagnostic performance of [68Ga]EDTA has
already been demonstrated in a clinical trial. [68Ga]IRDye800-tilmanocept shows receptor-mediated binding to glomerular
mesangial cells, which in turn may allow the monitoring of progression of diabetic nephropathy. [18F]FDS shows excellent
kidney extraction and excretion in rats and, as has been shown in the first study in humans. Further, due to its simple one-step
radiosynthesis via the most frequently used PET radiotracer 2-deoxy-2-[18F]fluoro-D-glucose, [18F]FDS could be available at
nearly every PET centre. A new PET radiotracer has also been introduced for the effective assessment of plasma flow in the
kidneys: Re(CO)3-N-([
18F]fluoroethyl)iminodiacetic acid (Re(CO)3([
18F]FEDA)). This compound demonstrates similar phar-
macokinetic properties to its 99mTc-labelled analogue [99mTc](CO)3(FEDA). Thus, if there is a shortage of molybdenum-99,
Re(CO)3([
18F]FEDAwould allow direct comparison with previous studies with 99mTc. The PET radiotracers for renal imaging
reviewed here allow thorough evaluation of kidney function, with the tremendous advantage of precise anatomical coregistration
with simultaneously acquired CT images and rapid three-dimensional imaging capability.
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Introduction
Glomerular filtration rate (GFR) is defined as the rate of plas-
ma flow through the glomerulus into the urinary space of the
Bowman’s capsule and is the most suitable index and key
indicator for renal function. A decrease in GFR to <60 ml/
min/1.73 m2 for ≥3 months is a common criterion for defining
chronic kidney disease and such a loss in GFR has been asso-
ciated with a higher risk of all-cause and cardiovascular mor-
tality [1]. In current clinical practice, GFR is estimated using
serum creatinine; however, this method can be inaccurate and
a separate assessment of individual renal function is not
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feasible [2, 3]. As the most accurate estimate of GFR, the
exogenous marker inulin is considered as the gold standard
for reliable assessment of GFR. However, because of techni-
cal difficulties and its high cost, it is seldom performed in
clinical practice [4]. Blood clearance determined using
[51Cr]ethylenediaminetetraacetic acid ([51Cr]EDTA) may be
an attractive alternative, but information about split renal func-
tion cannot be obtained and the need for multiple blood col-
lections limit its widespread use [5]. In this regard, a noninva-
sive metric, such as renal radionuclide imaging using single-
photon-emitting [99mTc]diethylenetriaminepentaacetic acid
([99mTc]DTPA), is regularly employed in clinical routine,
in particular as it offers the opportunity to determine split
renal function in the context of GFR estimation [6]. This
technique is quite well established in nuclear medicine
centres to calculate renal blood flow and to evaluate uni-
lateral kidney function, and its diagnostic performance has
been proven in a variety of clinical settings [7–9].
However, procedures with [99mTc]DTPA involving repeat-
ed blood and urinary measurements are a burden for both
patients and personnel, and such lengthy procedures may
also lead to noncompliance with procedural instructions,
and flaws in sample collection [10].
As another marker of renal function, effective renal
plasma flow (ERPF) can be derived from the clearance
of para-aminohippuric acid infusion. Although it serves
as a reference standard for ERPF assessment, this ap-
proach is not very well suited to clinical practice. Thus,
in recent years, [99mTc]mercaptoacetyltriglycine
([99mTc]MAG3) has been routinely used to measure tu-
bular extraction [11, 12]. However, Compton scatter and
soft-tissue attenuation may reduce diagnostic accuracy
and quantification reliability of these approaches. Of
note, hybrid imaging using single-photon emission com-
puted tomography/computed tomography (SPECT/CT)
may overcome these hurdles, as it offers three-
dimensional anatomical coregistration, but prolonged ac-
quisition times and low spatiotemporal resolution still
limit its potential for quantitative assessment [6, 13].
In contrast to conventional molecular imaging modalities,
positron emission tomography (PET) radiotracers for renal
functional assessment offer several key advantages, such as
better spatiotemporal resolution, absolute camera-based quan-
tification, and rapid three-dimensional imaging. In this re-
gard, multiple renal PET radiotracers to assess renal function
are currently under investigation, including [68Ga]EDTA,
[18F]Re(CO)3-N - ( f luoroethyl ) iminodiacet ic ac id
(Re(CO)3([
18F]FEDA)), and 2-deoxy-2-[18F]fluorosorbitol
([18F]FDS) [14–17] (Fig. 1).
We provide an overview of these PET radionuclides
for renal functional assessment, along with their under-
lying kinetic characteristics and potential uses in clinical
routine.
Quantitative data derived from a renal scan
The application of radionuclides to renal functional imaging is
based on radiotracer kinetics and kinetic modelling, and thus
renal molecular imaging allows reliable quantification. In this
regard, various parameters can be derived from a renal scan
and the quantitative information acquired includes, but is not
limited to:
– Renal perfusion: Renal perfusion can be determined by
visual and quantitative assessment of radiotracer transit
after injection (through the abdominal artery and renal
arteries) [18].
– Relative renal uptake: Relative renal uptake allows the
assessment of differential renal function, for example by
placing regions of interest (ROI) over the kidneys and mea-
suring the integral of the counts in the ROIs after radiotracer
injection [18]. Such split renal function assessments of the
left and the right kidneys are of the utmost importance for
living kidney donation, as disparity can significantly affect
whether a donation can still be performed [19].
– Maximal parenchymal activity (Tmax and T1/2max): Tmax is
defined as the time from injection to peak height of the
renogram, while T1/2max is the time for renal activity to
decrease to 50% of its maximum value. The latter param-
eter is routinely used as a simple means for assessing
renal obstruction. Although this parameter can be influ-
enced by various factors (hydration status, radiopharma-
ceutical used, presence of a bladder catheter), a broad
consensus exists that clearance with a T1/2max of
<10 min excludes the presence of obstruction [18, 20].
– Camera-based clearance: In contrast to plasma-based
sample techniques, collection of blood and urine samples
can be omitted for camera-based assessment of clearance.
Tracer accumulation in the kidneys is determined shortly
after injection of the radiotracer and divided by the counts
injected. The percentage injected dose to the kidneys is
converted to a clearance value (by comparison with a
validated normogram) [18].
Comparison of PET, single-photon planar
imaging and SPECT in assessing renal
function
Planar imaging techniques for renal radionuclide imaging
have several drawbacks, including limited spatiotemporal res-
olution and missing anatomical information. Notably, hybrid
imaging devices such as SPECT/CT scanners, allow three-
dimensional assessments and anatomical coregistration, al-
though these features are not commonly employed in clinical
routine due to prolonged acquisition and low single-pass
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extraction, which are seen as major obstacles to reliable dy-
namic imaging. In addition, corrections for soft-tissue attenu-
ation are required, e.g. by estimating renal depth or by apply-
ing an attenuation coefficient [21]. In contrast to SPECT, PET
offers multiple advantages that can be considered key features
for a more thorough evaluation of renal function. These in-
clude superior spatiotemporal resolution, absolute camera-
based quantification approaches and multislice CT for ana-
tomical co-registration.Most importantly, as compared to con-
ventional single-photon scintigraphy/SPECT, count rates are
significantly higher, which in turn may allow administration
of much lower doses of radioactivity. For example, for a renal
PET study with [68Ga]EDTA, 40 MBq is routinely adminis-
tered. The effective dose from the PET component is 1.6 mSv
and this equates to approximately 320 MBq of [99mTc]DTPA
[6, 15]. As a result, radiation exposure is minimized without
sacrificing image quality.
Consequently, the use of PET for renal imaging, including
estimation of GFR, may improve the identification of struc-
tural abnormalities and quantification of obstructive processes
in paediatric and adult subjects. In paediatric patients, the po-
tentially lower radiation dose from PET radiotracers may be of
particular importance, in particular if repeated renal studies are
necessary [3, 15]. The introduction of time-of-flight technol-
ogy, further improvements in detector technology and im-
proved reconstructive algorithms may allow further decreases
in the amount of administered activity [6]. Furthermore, the
intrinsic ability of renal PET to provide tomographic images
of the kidneys may allow elimination of background activity
from surrounding organs, such as major vessels and the spleen
[3]. Hence, time–activity curves may be generated from up-
take exclusively in the kidneys and an automatically applied
standardized uptake value threshold can be used to define
activity in the cortex and collecting system [6]. This is in
contrast to renal scintigraphy in which the ROI covers the
entire kidney to generate the renogram (Fig. 2). Moreover,
the accuracy of GFR obtained by SPECT agents such as
[99mTc]DTPA may also be adversely affected by pharmacoki-
netics. [99mTc]DTPA has been postulated to be more strongly
bound to plasma proteins than other radiotracers used for GFR
assessment. Indeed, protein binding has been shown to vary
by 10–13% and extracellular localization of DTPA may fur-
ther adversely affect diagnostic accuracy [22]. However, nov-
el PET radiotracers, such as [68Ga]EDTA, [18F]FDS and
Re(CO)3([
18F]FEDA), may have superior pharmacokinetic
profiles, mainly due to low plasma protein binding and high
metabolic stability (Fig. 1) [6, 14, 17].
68Ga-Labelled radiotracers for renal function
imaging
[68Ga]EDTA
Hofman and Hicks [6] were the first to report the use of the
PET probe [68Ga]EDTA, which is almost exclusively excreted
by glomerular filtration, for the assessment of renal function.
After administration, the radiotracer initially concentrates in
the blood pool, while the aorta (or heart) can potentially be
used to provide input functions for kinetic analysis. Over time,
activity increases in the renal cortex, followed by a gradual
delineation of the renal parenchyma and transit of the activity
into the collecting system, which can be observed 3–4 min
after injection (p.i.). In a study of 31 patients, Hofman et al.
[13] compared GFR estimates from [68Ga]EDTA PET/CT im-
aging and [68Ga]EDTA and [51Cr]EDTA plasma sampling.
Three time-points were defined for PET quantification: an
initial phase (1–2 min p.i.), a renal excretion phase (2–
10 min p.i.) and a late phase (reflecting urinary excretion into
the collecting system). GFR determined by the [51Cr]EDTA
and [68Ga]EDTA plasma sampling methods showed an excel-
lent correlation (Pearson correlation coefficient 0.94). GFR
from the late phase PET quantification showed the strongest
correlation with GFR from plasma sampling (correlation co-
efficient 0.9). The authors concluded that dynamic PET imag-
ing using [68Ga]EDTA is as a noninvasive GFR estimation
method with the additional advantage of hybrid renal imaging
in the same study.
The same group also studied a small series of 11 patients
with renal cell carcinoma who underwent both [99mTc]DMSA
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(planar imaging, SPECT/CT) and [68Ga]EDTA PET/CT prior
to stereotactic radiotherapy [6]. A significant discrepancy was
noted between DMSA planar and SPECT/CT imaging (most
probably owing to activity of adjacent overlying organs). Good
agreement between SPECT/CT and [68Ga]EDTA PET during
the excretory phase was found, whereas there was significant
disagreement between the two imaging modalities in the early
cortical phase, perhaps suggesting that [68Ga]EDTA may offer
additional information in split renal functional assessment dur-
ing the early phase of renal parenchymal transit [6].
[68Ga]DTPA
Given that 99mTc-labelled DTPA has been used for renal
functional assessment over decades, Gundel et al. [23] in-
vestigated the renal PET probe [68Ga]DTPA in a head-to-
head comparison with [68Ga]EDTA in vitro and in vivo in
male Copenhagen rats. Only 30% of the injected
[68Ga]DTPA activity was excreted via the kidneys (in con-
trast to almost 90% of [68Ga]EDTA activity). Of note,
compared to measured inulin clearance, [68Ga]DTPA led
to a marked underestimation of GFR by up to 80%. These
findings are most likely explained by the strong binding of
this radiotracer to plasma proteins [23]. Thus, compared to
[68Ga]DTPA, [68Ga]EDTA demonstrates superior diagnos-
tic performance in renal radionuclide PET imaging [6, 23].
[68Ga]1,4,7-Triazacyclononane-1,4,7-triacetic acid
([68Ga]NOTA)
Lee et al. [24] evaluated 68Ga complexes (EDTA, DTPA and
NOTA) and measured binding to serum and red blood cells,
along with a head-to-head-comparison of GFR measurements
with [51Cr]EDTA in mice. Notably, [68Ga]NOTA showed not
only low binding to serum proteins, but also comparable GFR
values to those obtained with the reference standard
[51Cr]EDTA. Thus, [68Ga]NOTA may also be an attractive
and easy-to-prepare renal PET agent [24]. However, compared
to [68Ga]EDTA, feasibility studies in human subjects are still
lacking [13]. In the 1960s, [68Ga]EDTA had already been tested
in patients with glioblastoma using a positron scintillation cam-
era with recording on Polaroid film [25]. Thus, compared to the
recently introduced [68Ga]NOTA, this long experience with
[68Ga]EDTA paved the way to the application of this radiotrac-
er to renal PET imaging during the last decade [6].
[68Ga]IRDye800-tilmanocept
Diabetic nephropathy is the leading cause of kidney failure
and is characterized by progressive expansion of the
mesangial matrix which finally occludes the glomerular cap-
illaries [26]. Recently, Qin et al. [27] introduced the novel PET
probe [68Ga]IRDye800-tilmanocept for the assessment of
GFR in a rat study and the time–activity curves derived
showed receptor-mediated renal accumulation with evidence
of glomerular uptake. Further, histological examination inves-
tigating the colocalization of the tilmanocept receptor
(CD206) and IRDye800-tilmanocept within the glomerulus
confirmed mesangial cell accumulation of the radiotracer. In
addition, diabetic and nondiabetic db/db mice underwent im-
aging with fluorescent-labelled [99mTc]tilmanocept. The non-
diabetic mice showed a single-phase time–activity curve with
low bladder accumulation, while the diabetic mice showed a
multi-phasic renal time–activity curve with high urinary blad-
der accumulation. Given the crucial role of the mesangial
matrix in progression of diabetic nephropathy, the authors
Fig. 2 Right and left kidneys in a 52-year-old woman who underwent
[99mTc]diethylenetriaminepentaacetic acid ([99mTc]DTPA) renal imaging
evaluation for living kidney donation. a Dorsal planar images of both
kidneys during imaging acquisition. b Regions of interest were placed
over the entire kidneys on planar images. c Time–activity curves for the
left kidney (red) and the right kidney (blue) show a normal renogramwith
a slightly better performance for the left kidney (GFR: left, 62 ml/min;
right, 58 ml/min)
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concluded that radiolabelled tilmanocept may be a novel
receptor-based PET or SPECT imaging biomarker for moni-
toring progression of this glomerular disease [27].
18F-Labelled radiotracers for renal function
imaging
18F-Labelled radiotracers have the advantage of lower posi-
tron energy with higher positron yield, which in turn opens the
door to the injection of a considerably lower amount of activ-
ity without sacrificing image quality, and improves the con-
trast and noise characteristics of the images [28]. Moreover,
18F has a significantly longer half-life (110 min) than 68Ga
(68 min), which allows delivery from central cyclotron facil-
ities to smaller hospitals [29, 30]. Cyclotron production also
allows nearly unlimited production of radionuclide in contrast
to generator production. In this regard, an incremental cost-
effectiveness ratio has already been proven for the most fre-
quent PET radiotracer 2-deoxy-2-[18F]fluoro-D-glucose
([18F]FDG) [31]. Moreover, the longer half-life also allows
more flexibility in study design, i.e. delayed imaging proto-
cols that may provide further insight into radionuclide han-
dling in the renal system. Of note, radiopharmaceuticals may
also benefit from fluoride introduction, as the risk of metabo-
lism at sensitive positions may be reduced [32]. In the follow-
ing sections, we provide an overview of 18F-labelled radio-
tracers currently used for renal imaging.
[18F]FDS
Initially, [18F]FDS was developed for imaging in oncology
and inflammatory diseases, in particular in clinical cases of
known or suspected infections caused by Enterobacteriaceae
[33, 34]. [18F]FDS can be easily synthesized by a simple one-
step reduction of [18F]FDG, and thus [18F]FDS may be avail-
able in the near-term at many sites that have radiochemistry
infrastructure (Fig. 3a) [35]. In early human studies, urinary
clearance of sorbitol was found to be almost identical to that of
inulin [36]. Given the underlying sorbitol structure of
[18F]FDS, one could speculate that it inherits kinetic features
almost identical to those of both sorbitol and inulin.
[18F]FDS was first investigated in healthy Wistar rats to
determine its basic biodistribution properties as a renal
PET probe, including clearance through the renal
collecting system pathway, plasma protein binding and
metabolic transformation. Dynamic PET images revealed
high renal radiotracer excretion in healthy animals. After
an initial blood flow phase through the inferior vena cava,
gradual delineation of the renal cortex was observed and
transit of the activity to the collecting system could be
appreciated. In addition, a time-dependent increase in ra-
diotracer activity in the bladder was seen (Fig. 3b). As
early as during during second frame (8–16 s), PET reno-
grams demonstrated rapid radiotracer uptake in the renal
cortex. Thereafter, a transient increase in radiotracer activ-
ity in the cortex, followed by transit to the collecting sys-
tem was seen in tomographic views (Fig. 3c). Split renal
function assessment demonstrated a normal renogram pat-
tern (Fig. 3d). In vivo biodistribution showed favourable
results, with the kidneys having the highest radiotracer
accumulation, even 60 min after injection. Of note, radio-
tracer concentrations in the intestines and liver remained
stable over time, suggesting low hepatobiliary clearance
and exclusive renal secretion of [18F]FDS. Post-mortem
tissue counting revealed almost identical values to its
SPECT coun te rpa r t [ 9 9mTc]DTPA. The lack of
radiolabelled metabolites in the blood and urine 35 min
a f t e r i n j e c t i o n wa s c o n f i rm e d b y t h i n - l a y e r
radiochromatography. This feasibility study in healthy rats
suggested that [18F]FDS is freely filtered at the renal glo-
merulus, and this is in line with previous findings showing
rapid clearance of exogenous administered sorbitol that is
identical to inulin clearance, as measured in dogs and
humans. Again, this may be explained by the underlying
sorbitol structure of [18F]FDS [14].
Plasma protein binding also has a major impact on radio-
nuclide radiotracer kinetics and is considered a major obstacle
to GFR estimation. GFR underestimation might occur, as only
the free fraction of the radiotracer is filtered at the glomerulus.
Protein binding of [99mTc]DTPA has been reported to range
from 2% to 10% [37, 38], whereas [18F]FDS demonstrates
minimal in-vivo serum protein binding of <0.1% [38].
In light of these encouraging findings, two rat models of
renal disorders have been investigated to determine the po-
tential clinical benefit of this radiotracer. First, acute renal
failure (ARF) was induced by intramuscular injection of
glycerol in the rats. Second, unilateral ureteral obstruction
(UUO) was obtained by complete ligation of the left ureter
near the renal pelvis. While healthy control rats showed a
normal distribution pattern, ARF rats showed a significantly
reduced uptake in the renal cortex along with relatively low
excretion through the urinary collecting system (Fig. 4a, b).
Renograms showed a nonfunctioning pattern, with lower
radiotracer secretion via the kidneys in ARF rats than in
healthy control rats (Fig. 4c). On the other hand, UUO rats
demonstrated significantly delayed uptake on the obstructed
left side, with no transit into the collecting system. This
observation was in contrast to the contralateral nonaffected
kidney that demonstrated normal distribution of [18F]FDS
(Fig. 5a, b). Renograms showed a typical obstructed pattern,
with no further peak during the parenchymal phase and pro-
gressive parenchymal accumulation (Fig. 5c) [15].
In the first study in humans investigating the use of
[18F]FDS, dynamic [18F]FDS PET was performed in two
healthy volunteers. The radiotracer was shown to pass through
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the renal parenchyma and transit into the collecting system.
The radiotracer gradually increased in the renal parenchyma
up to 60 s after administration (i.e. blood flow) and was then
excreted. Derived split functional renograms demonstrated a
normal pattern in both volunteers and comprised blood flow,
parenchymal and excretory phases (Fig. 6a, b). Volumes of
Fig. 3 a [18F]Fluorodeoxysorbitol ([18F]FDS) radiotracer synthesis.
[18F]FDS can be produced by methods adapted from Li et al. utilizing a
simple one-step reduction from 2-deoxy-2-[18F]fluoro-D-glucose
([18F]FDG) [35]. b–d In vivo [18F]FDS PET imaging in healthy rats. b
Whole-body dynamic coronal PET images show high tracer secretion
exclusively via the kidneys and a time-dependent increase in bladder
activity. c Dynamic transverse and coronal images of the right kidney
show rapid tracer accumulation in the renal cortex and tracer transit into
the collecting system. d Example time–activity curves for the kidneys
(left) and bladder (right) assessed by dynamic PET imaging. Modified
from Wakabayashi et al. [14]
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interest covering the renal cortex as well as the renal medulla
confirmed successive transit of the radiotracer through the
kidneys (Fig. 6c). The derived maximal parenchymal activity
(Tmax, 3 min after injection) is in line with findings for
[99mTc]DTPA and [99mTc]MAG3 [39]. No adverse effects
due to [18F]FDS administration were reported [40].
Re(CO)3([
18F]FEDA)
In contrast to [68Ga]EDTA and [18F]FDS that are mainly used
for the assessment of GFR, efforts in recent years have focused
on developing and investigating other renal PET probes that
reflect tubular function and ERPF, e.g. Re(CO)3([
18F]FEDA)
and its SPECT analogue [99mTc](CO)3(FEDA) [3].
[99mTc](CO)3(FEDA) shows rapid renal excretion similar to
that of [131I]orthoidodohippurate ([131I]OIH) in rats [16, 41].
Based on these encouraging results, the authors demonstrated
similar findings by developing an efficient, one-step
radiosynthesis of an 18F-Re-tricarbonyl PET tracer, namely
Re(CO)3([
18F]FEDA). Re(CO)3([
18F]FEDA) shows high renal
specificity, high in vitro and in vivo stability and rapid renal
excretion, which are comparable to those of its analogue
[99mTc](CO)3(FEDA) [17]. The pharmacokinetic properties of
Re(CO)3([
18F]FEDA) are also comparable to those of
[131I]OIH, which is considered the reference standard for
ERPF measurement [17, 42]. As a component of a pair of
analogous 18F/99mTc renal imaging agents with almost identical
kinetic properties, [99mTc](CO)3(FEDA) could be available as a
kit which is five times cheaper than Re(CO)3([
18F]FEDA).
However, if there is a shortage of 99Mo that would lead to
[99mTc](CO)3(FEDA) becoming unavailable, it could be re-
placed by the analogous PET radiotracer. Such an approach
would allow direct comparisons between a previous
[99mTc](CO)3(FEDA) SPECT study and a subsequent
Re(CO)3([
18F]FEDA) PET study [17].
Al[18F]NODA-butyric acid
Biodistribution studies in normal rats and rats with simulated
renal failure (by ligation of the renal pedicles) have revealed
that Al[18F]NODA-butyric acid is exclusively secreted
through the renal system. Thus, this radiotracer may also pro-
vide reliable estimates of ERPF [43].
p-[18F]Fluorohippurate ([18F]PFH)
Because of its similar structure to p-aminohippurate, which is
considered the gold standard for ERPF measurement,
[18F]PFH was identified by Awasthi et al. as a potential renal
PET imaging agent [44]. Pathuri et al. [45] investigated this
compound in healthy rats and compared the renogram patterns
with those obtained with the gold standards [125I]OIH and
[99mTc]MAG3. Notably, compared with the derived renogram
parameters (Tmax, T1/2max) obtained with [
99mTc]MAG3, the
parameters obtained with [18F]PFH were closer to those ob-
tained with [125I]OIH, and [18F]PFH also provided better im-
age quality [45]. Another study in Han:SPRD rats with slowly
progressive autosomal dominant polycystic kidney disease
showed that [18F]PFH could be a surrogate marker for disease
progression, which further emphasizes the potential clinical
utility of this agent in future translational approaches [46].
[18F]FDG
[18F]FDG is involved in multiple physiological processes and
thus may not be an ideal PET agent to assess renal function.
However, as [18F]FDG is also considered the Bworkhorse^ in
nuclear oncology imaging, it would be of great benefit if basic
kidney parameters could be derived from a routine [18F]FDG
scan. In a study by Geist et al. [47], 24 healthy volunteers
underwent [18F]FDG dynamic PET/magnetic resonance im-
aging, and Patlak analysis was performed to determine GFR
and ERPF. These quantitative indices correlated with both
[99mTc]MAG3 tubular extraction rate and blood-based creati-
nine clearance in an acceptable range (R = 0.73–0.78).
Table 1 summarizes the key properties and limitations of
the 68Ga-labelled and 18F-labelled PET radiotracers reviewed.
Clinical indications for renal PET imaging
PET offers several advantages over conventional scintigraphy,
although the high costs of PET studies are a consideration in
deciding the extent to which such PET radiotracers can be
employed in clinical routine. In addition, another major obstacle
in using renal PET imaging in humans has to be addressed:
current PET cameras may not allow imaging of the entire uri-
nary system in a single field of view. Barring the purchase of
longer-bore scanners specifically for renal functional imaging
evaluation, a solution to this problem is multi-bed-position PET
acquisitions, which may adversely affect diagnostic accuracy
[13, 15]. In this regard, one may speculate as to the pathophys-
iological conditions that would justify the use of such an ex-
pensive and complex noninvasive metric to measure renal func-
tion [3]. [68Ga]EDTA may be ideal for monitoring haemody-
namically significant renal artery stenosis, as the short half-life
of 68Ga allows completion of a captopril renal study in a single
day [6, 48]. Blaufox and others have suggested that monitoring
renal function during chemotherapy and assessment of split
renal function (e.g. prior to living kidney donation or radiation
therapy) may be suitable indications for renal PET imaging [3,
49–51]. Notably, common scintigraphy/SPECT approaches
may lead to underestimation of the relative functional perfor-
mance of one of the kidneys (e.g. caused bymalrotation), which
may have a significant impact on the eligibility of a living donor
for donating a kidney for transplantation [52, 53]. Hybrid PET/
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CT to assess renal function including the most modern multi-
slice CT scanners for anatomical coregistration may be helpful
to guide the treating urologist or nephrologist in identifying
appropriate donor candidates [3].
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Apart from these considerations, theranostic approaches to the
treatment of neuroendocrine tumours (NET) using [68Ga]DOTA-
D-Phe-Tyr3-octreotate/octreotide ([68Ga]DOTA-TATE/TOC)
PETand [177Lu]DOTA-TATE/TOC are increasingly being used,
in particular due to the encouraging results of a recent random-
ized, controlled trial in midgut NET [54]. However, radiolabelled
somatostatin analogues can cause a decline in renal function and
it has been hypothesized that [99mTc]MAG3 might be a suitable
means of evaluating early stages of renal deterioration in patients
who have undergone repeated cycles of endoradiotherapy.
Although radiolabelled somatostatin analogues most likely pro-
voke a cross-fire effect from adjacent tubules, the tubular extrac-
tion rate measured by [99mTc]MAG3 could not identify high-risk
patients with a late onset of renal failure [12]. Thus, the PET
agents reviewed here for ERPF assessment, including
Fig. 5 In vivo [18F]FDS PET imaging in rats with unilateral ureteral
obstruction (UUO). a Dynamic coronal images show reduced tracer
uptake in the renal cortex of the UUO kidney, but rapid tracer uptake in
the renal cortex of the contralateral kidney. bWhole-body dynamic axial
and coronal PET images show no excretion of [18F]FDS into the renal
pelvis from the UUO kidney, but excretion of [18F]FDS into the renal
pelvis from the contralateral kidney at 0–5 min. A time-dependent in-
crease in renal uptake can be seen in the UUO kidney. c Average time–
activity curves for the kidneys obtained by dynamic PET imaging indicate
tracer deposition in the renal cortex of the UUO kidney. Modified from
Werner et al. [15]; copyright Society of Nuclear Medicine and Molecular
Imaging, Inc.
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Fig. 4 In vivo [18F]FDS PET imaging in control rats and acute renal
failure (ARF) rats. a Dynamic coronal images of the left kidney show
rapid tracer uptake in the renal cortex in the control rat, but reduced tracer
uptake in the renal cortex in the ARF rat. bWhole-body dynamic coronal
PET images show high tracer secretion exclusively via the kidneys and a
time-dependent increase in bladder activity in the control rat, but reduced
renal tracer secretion via the kidneys and a delayed increase in bladder
activity in the ARF rat. c Average time–activity curves for the kidneys
(top) and bladder (bottom) obtained by dynamic PET imaging indicate
low tracer secretion via the kidneys in the ARF rat.Modified fromWerner
et al. [15]; copyright Society of Nuclear Medicine and Molecular
Imaging, Inc.
Re(CO)3([
18F]FEDA) and [18F]PFH, may be better surrogate
markers for identifying patients most at risk. This may also apply
to other endoradiotherapies with a potential nephrotoxic profile,
e.g. in patients with haematopoietic malignancies treatedwith the
CXC-chemokine receptor 4 ligand [177Lu]/ [90Y]pentixather
or in prostate cancer patients scheduled for prostate-
specific membrane antigen to enable beta particle thera-
py [55, 56].
Fig. 6 [18F]FDS PET/CT imaging of the right kidney in a 48-year old
female volunteer. Dynamic coronal images (a) and axial, coronal and
sagittal images (b) show rapid radiotracer accumulation in the renal cor-
tex, followed by radiotracer excretion. c Average time–activity curves
obtained by dynamic PET imaging. Three-dimensional (3D) volumes of
interest (VOIs) were placed on the outer layer (corresponding to the
cortex, green) as well as on the middle layer (blue) and inner layer
(orange) corresponding to the medulla. Modified from Werner et al. [40]
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However, we and others see the most relevant indication of
renal PET/CT in paediatric patients [3, 6, 14]. Creatinine
clearance-based GFR estimates are routinely performed in
children, but variability in body mass limit their reliability,
and accuracy is also altered in those with renal and urological
disorders [3]. In addition, renal anatomical abnormalities are
frequently observed in toddlers and younger adults (e.g.
ureteropelvic junction obstruction) [57]. Hence, renal PET
may open the door to effective decision making in paediatric
patients, as it allows simultaneous assessment of renal func-
tion and anatomical coregistration in a single study.
Additionally, count rates with PET are higher than with con-
ventional scintigraphy, and thus a much lower activities can be
administered [6].
Conclusion
In recent years, a shift from single-photon-emitting to PET
radiotracers has occurred in a variety of clinical settings
[58–60], and thus the concept of PET has also been applied
to renal radionuclide imaging. In this regard, several novel
PET radiotracers for the assessment of renal function are cur-
rently emerging: the GFR-reflect ing PET probes
[68Ga]EDTA, [68Ga]IRDye800-tilmanocept and [18F]FDS,
and the tubular agent Re(CO)3([
18F]FEDA) [6, 13–15, 17,
27]. [68Ga]EDTA is the only agent to date that has already
been evaluated in a large clinical trial [13]. [68Ga]IRDye800-
tilmanocept shows receptor-mediated binding to glomerular
mesangial cells, which in turn may allow monitoring of pro-
gression of diabetic nephropathy [27]. In contrast to 68Ga-
labelled radiotracers, [18F]FDS has all the advantages of an
18F-labelled radionuclide, such as lower positron energy with
higher positron yield and longer physical half-life, which al-
lows distribution by commercial vendors [29, 32]. Apart from
these GFR-estimating radiotracers, the analogous pair
[99mTc](CO)3(FEDA)/Re(CO)3([
18F]FEDA) reflects ERPF
and both tubular agents are comparable to the radiotracer ref-
erence standard for ERPF assessment, [131I]OIH [17, 41].
Renal PET may have incremental value in challeng-
ing clinical situations and could provide effective deci-
sion support, in particular in paediatric patients. Further
research exploring the potential benefit over convention-
al scintigraphy/SPECT agents and larger clinical trials to
identify the most suitable clinical indications and scan
timing for each renal PET radiotracer are warranted.
Efforts should also turn toward synthesizing novel
(SPECT or PET) renal radiotracers that have ideal prop-
erties for renal functional imaging, e.g. exclusive kidney
extraction and excretion, low plasma protein binding,
high metabolic stability, low hepatobiliary clearance,
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